IL-15 and IL-15R\alpha sushi domain based immunocytokines

Patent metadata

Field	Value
Publication number	US-11753454-B2
Application number	US-202017068628-A
Country	US
Kind code	B2
Filing date	Oct 12, 2020
Priority date	Jun 24, 2011
Publication date	Sep 12, 2023
Grant date	Sep 12, 2023

Abstract

The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and (ii) a polypeptide comprising the amino acid sequence of the sushi domain of the interleukin 15R alpha (IL-15Rα) or derivatives thereof; and uses thereof.

First claim

We claim:

1. An isolated nucleic acid encoding a receptor-linker-interleukin (RLI) conjugate comprising an amino acid sequence represented by SEQ ID NO: 17.

2. An isolated vector comprising the nucleic acid of claim 1 .

3. An isolated host cell comprising the nucleic acid of claim 1 .

4. An isolated host cell comprising the vector of claim 2 .

5. The isolated host cell of claim 3 , wherein the host cell is selected from a bacterial, fungal, yeast, or animal cell.

6. The isolated host cell of claim 4 , wherein the host cell is selected from a bacterial, fungal, yeast, or animal cell.

7. The isolated host cell of claim 5 , wherein the animal cell is a Chinese hamster ovary (CHO) cell or COS cell.

8. The isolated host cell of claim 6 , wherein the animal cell is a Chinese hamster ovary (CHO) cell or COS cell.

9. A pharmaceutical composition comprising the nucleic acid of claim 1 .

10. A pharmaceutical composition comprising the vector of claim 2 .

11. A method of producing a cell genetically engineered to express the conjugate of claim 1 , said method comprising the steps of:
(i) introducing in vitro or ex vivo a nucleic acid of claim 1 or a vector comprising said nucleic acid into a host cell to provide a recombinant host cell;
(ii) culturing in vitro or ex vivo the recombinant host cell; and
(iii) optionally, selecting the recombinant host cells which express, secrete or both express and secrete the conjugate.

Assignees

• Cytune Pharma
• Inst Nat Sante Rech Med

Inventors

• Morisseau Sebastien Daniel
• Teppaz Geraldine
• Jacques Yannick Laurent Joseph
• Robert Bruno Gilbert Marc
• De Martynoff Guy Luc Michel
• Bechard David

Classifications

• A61K2039/54

  characterised by the route of administration · CPC title

• A61K39/39558

  against tumor tissues, cells, antigens · CPC title

• A61K38/2086 Primary

  IL-13 to IL-16 · CPC title

• C07K14/5443 Primary

  IL-15 · CPC title

• C07K14/7155

  for interleukins [IL] · CPC title